EyePoint Pharmaceuticals ... (EYPT)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.
The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.
It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC.
It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery.
The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.
EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Country | United States |
IPO Date | Jan 27, 2005 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 121 |
CEO | Dr. Jay S. Duker M.D. |
Contact Details
Address: 480 Pleasant Street Watertown, Massachusetts United States | |
Website | https://eyepointpharma.com |
Stock Details
Ticker Symbol | EYPT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001314102 |
CUSIP Number | 30233G209 |
ISIN Number | US30233G2093 |
Employer ID | 26-2774444 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Dr. Jay S. Duker M.D. | President, Chief Executive Officer & Director |
George O. Elston CPA | Executive Vice President & Chief Financial Officer |
Jennifer Leonard | Chief People Officer & Senior Vice President of IT |
Ron I. Honig Esq. | Chief Legal Officer & Company Secretary |
David Scott Jones M.A. | Senior Vice President & Chief Commercial Officer |
Dr. Marcia Sellos-Moura Ph.D. | Senior Vice President and Head of Development & Program Management |
Dr. Ramiro Ribeiro M.D., Ph.D. | Chief Medical Officer |
Isabelle Lefebvre | Chief Regulatory Officer |
Michael Pine | Chief Business Officer |
Michael J. Maciocio | Chief Manufacturing Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 27, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 13, 2025 | 8-K | Current Report |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 3 | Filing |
Jan 08, 2025 | 8-K | Current Report |
Jan 07, 2025 | 4 | Filing |
Jan 07, 2025 | 4 | Filing |
Jan 07, 2025 | 4 | Filing |
Jan 07, 2025 | 4 | Filing |
Jan 07, 2025 | 4 | Filing |